PRINCETON, N.J., July 23, 2009 (GLOBE NEWSWIRE) -- Orchid Cellmark Inc. (Nasdaq:ORCH), a leading worldwide provider of identity DNA testing services, will release its second quarter 2009 financial results on Thursday, July 30, 2009 at approximately 7:00 a.m. EDT, and is hosting a conference call and webcast to discuss the results at 10:00 a.m. EDT on the same day. Management will discuss financial results for the 2009 second quarter as well as operating highlights. A question-and-answer session will follow management's discussion.
All interested parties are encouraged to listen to the live conference call or to the live or archived webcast. A slide presentation by management will be available for viewing on the webcast and will be posted on the Investor Relations page of www.orchidcellmark.com shortly after the call. Questions will be taken live via the conference call.
Conference Call and Webcast Details
Date and Time: Thursday, July 30, 2009 at 10:00 a.m. EDT
Dial-In: US/Canada: 1-888-893-7720
Int'l/Local: 1-706-758-5085
Conference ID: 21542973
Webcast Details: Please register in advance for the live webcast at
the Investor Relations section of the company's
website at www.orchidcellmark.com. The webcast will
be available for 90 days following the event.
About Orchid Cellmark
Orchid Cellmark (Nasdaq:ORCH) is a leading international provider of DNA testing services primarily for forensic and family relationship applications. Orchid Cellmark is one of the largest providers of forensic DNA testing services and its DNA results are used by the criminal justice system to assist with the identification of perpetrators, the exclusion of suspects and the exoneration of wrongfully convicted individuals. The company provides DNA family relationship testing to numerous child services organizations and individuals seeking to verify parentage. Orchid Cellmark also serves immigration and security authorities for DNA testing of individuals. In the agriculture field, the company provides DNA testing services for selective trait breeding. Orchid Cellmark's strong market positions in these areas reflect the company's accredited laboratories in the U.S. and U.K., its innovative genetic analysis technologies and expertise, and the company's reputation for exceptional quality, reliability and customer service for nearly two decades. More information on Orchid Cellmark can be found at www.orchidcellmark.com.
CONTACT: Orchid Cellmark Inc.
Investors:
Thomas Bologna, CEO
James F. Smith, CFO
(609) 750-6436
jsmith@orchid.com
The Torrenzano Group
Media:
Rick Anderson
(212) 681-1700
randerson@torrenzano.com
